Development of a population pharmacokinetic model for the novel long‐acting injectable antipsychotic risperidone ISM® - Laveille - British Journal of Clinical Pharmacology - Wiley Online Library
The aims of this study were to develop a population pharmacokinetic (PK) model for risperidone ISM® and to investigate the relationships between active moiety exposure, as described by apparent clearance (CL40), and several covariates using all data from five clinical studies. Open access article - no login required